Fungemia and other Fungal Infections Associated with Use of Saccharomyces boulardii Probiotic Supplements

Because of widespread use of probiotics, their safety must be guaranteed. We assessed use of Saccharomyces boulardii probiotic yeast from medical records for patients who had Saccharomyces fungemia or other clinical Saccharomyces culture findings. We evaluated all Saccharomyces sp. findings at 5 university hospitals in Finland during 2009-2018. We found 46 patients who had Saccharomyces fungemia; at least 20 (43%) were using S. boulardii probiotic. Compared with a control group that had bacteremia or candidemia, the odds ratio for use of an S. boulardii probiotic was 14 (95% CI 4-44). Of 1,153 nonblood culture findings, the history for 125 patients was checked; at least 24 (19%) were using the probiotic (odds ratio 10, 95% CI 3-32). This study adds to published fungemia cases linked to use of S. boulardii probiotic and sheds light on the scale of nonblood Saccharomyces culture findings that are also linked to use of this probiotic.Peer reviewe

Fungemia and Other Fungal Infections Associated with Use of Saccharomyces boulardii Probiotic Supplements

Because of widespread use of probiotics, their safety must be guaranteed. We assessed use of Saccharomyces boulardii probiotic yeast from medical records for patients who had Saccharomyces fungemia or other clinical Saccharomyces culture findings. We evaluated all Saccharomyces sp. findings at 5 university hospitals in Finland during 2009–2018. We found 46 patients who had Saccharomyces fungemia; at least 20 (43%) were using S. boulardii probiotic. Compared with a control group that had bacteremia or candidemia, the odds ratio for use of an S. boulardii probiotic was 14 (95% CI 4–44). Of 1,153 nonblood culture findings, the history for 125 patients was checked; at least 24 (19%) were using the probiotic (odds ratio 10, 95% CI 3–32). This study adds to published fungemia cases linked to use of S. boulardii probiotic and sheds light on the scale of nonblood Saccharomyces culture findings that are also linked to use of this probiotic.</p

mHealth-interventioiden hyödyntäminen diabeteksen hoidossa

Diabetes on maailmanlaajuinen ongelma ja se aiheuttaa 12 prosenttia maailman terveysmenoista. Jo yli 10 prosenttia maailman väestöstä sairastaa diabetesta ja uusien tapausten ilmaantuvuus on kasvanut viime vuosina merkittävästi, joten tarve hoitomuotojen kehittämiselle ja diabeteksen ennaltaehkäisemiselle on suuri. mHealth-interventiot tarjoavat lupaavia ratkaisuja näihin haasteisiin. Tässä tutkielmassa tarkastellaan ensin, millaisia hyötyjä mHealth-interventioiden käytöllä voidaan saavuttaa diabeteksen hoidossa ja ennaltaehkäisyssä. Tämän jälkeen pohditaan mHealth-interventioiden käyttöön liittyviä haasteita ja niihin ratkaisuja. Tutkielma toteutettiin kirjallisuuskatsauksena aiheen aiemman tutkimuksen pohjalta. Johtopäätöksinä todettiin, että mHealth-interventioilla on potentiaalia tarjota hyötyjä diabeteksen hoitoon ja ennaltaehkäisyyn, mutta aiheesta tehty aiempi tutkimus on monelta osin puutteellista, joten lisätutkimusta tarvitaan tulevaisuudessa. Lisäksi aiemmassa tutkimuksessa korostui potilaiden sitoutumisen ja motivaation tärkeys mHealth-interventioiden hyötyjen saavuttamiseksi.Diabetes is a global problem, and it accounts for 12 percent of the world's health expenses. Over 10 percent of the world population suffers from diabetes and the incidence of new cases has increased significantly in recent years, so there is a great need for the development and prevention of diabetes treatment methods. mHealth interventions offer promising solutions to these challenges. This study examines the benefits of using mHealth interventions in the treatment and prevention of diabetes. After that, we consider the challenges of using mHealth interventions and solutions to those challenges. The study was conducted as a literature review based on previous research on the topic. As a result, it was found that mHealth interventions have the potential to provide benefits in the treatment and prevention of diabetes, but previous research on the subject is often deficient, so further research is needed in the future. In addition, previous research emphasized the importance of patient engagement and motivation in achieving the maximum benefits of mHealth interventions